CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 1, 2013, Pages 41-49

  El Halabi, Mustapha M ^a   Zgheib, Nathalie ^a   Mansour, Nabil M ^a   Malli, Ahmad ^a   Ghaith, Ola A ^a   Mahfouz, Rami ^a   Alam, Samir ^a   Sharara, Ala I ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

CYP450; drug interaction; high on treatment platelet reactivity; metabolism; pharmacodynamic; platelet reactivity index; proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; ESOMEPRAZOLE; PROSTAGLANDIN E1; RABEPRAZOLE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

AGED; ARYL HYDROCARBON HYDROXYLASES; BLOOD PLATELETS; COHORT STUDIES; ESOMEPRAZOLE; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RABEPRAZOLE; TICLOPIDINE;

EID: 84880570065     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31828ecf44     Document Type: Article

References (74)

1. Wright RS, Anderson JL, Adams CD, et al. 2011 accf/aha focused update of the guidelines for the management of patients with unstable angina/non-st- elevation myocardial infarction (updating the 2007 guideline): a report of the american college of cardiology foundation/american heart association task force on practice guidelines developed in collaboration with the american college of emergency physicians, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. 2011;57:1920-1959.
2. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome p450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-99.
3. Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992;44:527-532.
4. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84:891-896.
5. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the united states. Gastroenterology. 2002;122: 1500-1511.
6. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
7. Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to cyp2c19 genotypes. Aliment Pharmacol Ther. 2001;15:793-803.
8. Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors-focus on rabeprazole. Aliment Pharmacol Ther. 2004;20(suppl 6):11-19.
9. Bhatt DL, Scheiman J, Abraham NS, et al. Accf/acg/aha 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and nsaid use: a report of the American college of cardiology foundation task force on clinical expert consensus documents. J Am Coll Cardiol. 2008;52:1502-1517.
10. Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4:2508-2509.
11. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind ocla (omeprazole clopidogrel aspirin) study. J Am Coll Cardiol. 2008;51:256-260.
12. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909-1917.
13. Kwok CS, Jeevanantham V, Dawn B, et al. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. Mar 29, 2012 [Epub ahead of print].
14. Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome p450 2c19 genotype in a large nationwide cohort of acute myocardial infarction: results from the french registry of acute st-elevation and non-st-elevation myocardial infarction (fast-mi) registry. Circulation. 2011;123:474-482.
15. Schmidt M, Johansen MB, Robertson DJ, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther. 2012;35:165-174.
16. Siller-Matula JM, Jilma B, Schror K, et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:2624-2641.
17. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogreltreated patients according to cytochrome p450 2c19.2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56:134-143.
18. Wallentin L, James S, Storey RF, et al. Effect of cyp2c19 and abcb1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the plato trial. Lancet. 2010;376:1320-1328.
19. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome p450 2c19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010;55:2427-2434.
20. Pare G, Mehta SR, Yusuf S, et al. Effects of cyp2c19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704-1714.
21. Bauer T, Bouman HJ, van Werkum JW, et al. Impact of cyp2c19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ. 2011;343:d4588.
22. Holmes MV, Perel P, Shah T, et al. Cyp2c19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-analysis. JAMA. 2011;306:2704-2714.
23. US-Food-and-Drug-Administration (2009) Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm. Accessed May 20, 2012.
24. US-Food-and-Drug-Administration (2010) FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed May 20, 2012.
25. Tran M, Tafreshi J, Pai RG. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians. J Cardiovasc Pharmacol Ther. 2010;15:326-337.
26. Fock KM, Ang TL, Bee LC, et al. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 2008;47:1-6.
27. Abraham NS, Hlatky MA, Antman EM, et al. Accf/acg/aha 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the accf/acg/aha 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and nsaid use. A report of the american college of cardiology foundation task force on expert consensus documents. J Am Coll Cardiol. 2010;56:2051-2066.
28. Schwarz UR, Geiger J, Walter U, et al. Flow cytometry analysis of intracellular vasp phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost. 1999;82: 1145-1152.
29. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv. 2003;59:295-302.
30. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-933.
31. Flockhart D (2007) Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at http://medicine. iupui.edu/clinpharm/ddis/table.aspx. Accessed 6 May 2012.
32. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet vasp phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. 2005;3:85-92.
33. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171-3175.
34. Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf. 2012;35:127-139.
35. Jaspers Focks J, Brouwer MA, van Oijen MG, et al. Concomitant use of clopidogrel and proton pump inhibitors: Impact on platelet function and clinical outcome a systematic review. Heart. 2013;99:520-527.
36. Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors where do we stand in 2012? World J Gastroenterol. 2012;18: 2161-2171.
37. Cai J, Wu Q, Fan L, et al. Iimpact of different proton pump inhibitors on the antiplatelet activity of clopidogrel in combination with aspirin for patients undergoing coronary stent implantation [in Chinese]. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2010;26:266-269.
38. Guo Q, Jin W. Effects of esomeprazole and omeprazole on clopidogrel platelet inhibition following cardiac stent implantation [in chinese]. J Clin Rehab Tissue Engineering Res. 2009;13:10283-10286.
39. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89:65-74.
40. Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to cyp2c19 genotypes. Br J Clin Pharmacol. 2010;70:383-392.
41. Yun KH, Rhee SJ, Park HY, et al. Effects of omeprazole on the antiplatelet activity of clopidogrel. Int Heart J. 2010;51:13-16.
42. Gremmel T, Steiner S, Seidinger D, et al. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc Pharmacol. 2010;56: 532-539.
43. Neubauer H, Engelhardt A, Kruger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol. 2010;56: 91-97.
44. Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 q192r genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J. 2011;32:1605-1613.
45. Frelinger AL III, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59:1304-1311.
46. Ren YH, Zhao M, Chen YD, et al. Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. Chin Med J (Engl). 2011;124:856-861.
47. Harmsze AM, van Werkum JW, Souverein PC, et al. Combined influence of proton-pump inhibitors, calcium-channel blockers and cyp2c19.2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost. 2011;9:1892-1901.
48. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101: 714-719.
49. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009; 157:148 e141-148 e145.
50. Hsu PI, Lai KH, Liu CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 2011;140:791-798.
51. Zhang R, Ran HH, Zhu HL, et al. Differential effects of esomeprazole on the antiplatelet activity of clopidogrel in healthy individuals and patients after coronary stent implantation. J Int Med Res. 2010;38:1617-1625.
52. Harmsze AM, van Werkum JW, Taubert D, et al. Esomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel's active metabolite. Ann Pharmacother. 2011;45:542-543.
53. Fernando H, Bassler N, Habersberger J, et al. Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J Thromb Haemost. 2011;9:1582-1589.
54. Tunggal P, Ng FH, Lam KF, et al. Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial. Am Heart J. 2011;162:870-874.
55. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48:475-484.
56. Hulot JS, Wuerzner G, Bachelot-Loza C, et al. Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in cyp2c19-genotyped healthy subjects. J Thromb Haemost. 2010;8:610-613.
57. Kwan J, Htun WW, Huang Y, et al. Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in chinese patients with percutaneous coronary intervention. Vasc Health Risk Manag. 2011;7: 399-404.
58. Nagata Y, Inomata JI, Kinoshita M, et al. Impact of proton pump inhibitors or famotidine on the antiplatelet actions during dual-antiplatelet therapy in japanese patients. Cardiovasc Interv Ther. 2013;28:22-29.
59. Uotani T, Sugimoto M, Nishino M, et al. Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on cyp2c19 genotype. Clin Gastroenterol Hepatol. 2012;10: 879-885 e2.
60. Wu J, Jia LT, Shao LM, et al. Drug-drug interaction of rabeprazole and clopidogrel in healthy chinese volunteers. Eur J Clin Pharmacol. 2013; 69:179-187.
61. Yamane K, Kato Y, Tazaki J, et al. Effects of ppis and an h2 blocker on the antiplatelet function of clopidogrel in japanese patients under dual antiplatelet therapy. J Atheroscler Thromb. 2012;19:559-569.
62. Siriswangvat S, Sansanayudh N, Nathisuwan S, et al. Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. Circ J. 2010;74:2187-2192.
63. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome p450-2c19 (cyp2c19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90:328-332.
64. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome p450 2c19 681g.a polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925-1934.
65. Giusti B, Gori AM, Marcucci R, et al. Cytochrome p450 2c19 loss-offunction polymorphism, but not cyp3a4 ivs10 + 12g/a and p2y12 t744c polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007;17:1057-1064.
66. Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol. 2008;101:1088-1093.
67. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
68. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360:363-375.
69. Collet JP, Hulot JS, Pena A, et al. Cytochrome p450 2c19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373:309-317.
70. Sawada T, Shinke T, Shite J, et al. Impact of cytochrome p450 2c19.2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in japanese patients receiving clopidogrel. Circ J. 2010;75:99-105.
71. Bouman HJ, Harmsze AM, van Werkum JW, et al. Variability in ontreatment platelet reactivity explained by cyp2c19.2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart. 2011;97:1239-1244.
72. Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: Approaches to the FDA "Boxed warning": a report of the american college of cardiology foundation task force on clinical expert consensus documents and the american heart association endorsed by the society for cardiovascular angiography and interventions and the society of thoracic surgeons. J Am Coll Cardiol. 2010;56: 321-341.
73. Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17:110-116.
74. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-1309.